Literature DB >> 15291011

Zolpidem 'as needed': methodological issues and clinical findings.

Raymond Cluydts1.   

Abstract

This article introduces 'as needed' hypnotic treatment as a possible option in the psychopharmacological treatment for chronic but non-daily occurring insomnia complaints. This treatment option is a well-structured regimen designed by both patient and treating physician. It aims at providing symptomatic relief for sleepless nights and preventing the development of possible dependence on the hypnotic agent. A significant amount of responsibility regarding the necessary accompanying lifestyle changes remains in the patient's hands. This paper describes three of the early experiments designed as a 'proof of concept'. All three studies demonstrated that zolpidem can be used effectively and safely on a non-daily basis in individuals with chronic insomnia. Although these studies have methodological limitations, they opened doors to well-designed clinical trials in both in and outpatients. The scientific validation of this therapeutic approach is still in progress. In addition to sleep laboratory studies, ecological studies are needed to investigate pill-taking behaviour and the risk of dependence over a long period of time in real life settings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15291011     DOI: 10.2165/00023210-200418001-00006

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  11 in total

1.  Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.

Authors:  S Ancoli-Israel; T Roth
Journal:  Sleep       Date:  1999-05-01       Impact factor: 5.849

2.  Polysomnographic findings during non-continuous administration of zolpidem.

Authors:  Raymond Cluydts; Karin Heyde; Ilse De Volder
Journal:  Sleep Med Rev       Date:  2002-10       Impact factor: 11.609

Review 3.  Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?

Authors:  M H Lader
Journal:  Eur Neuropsychopharmacol       Date:  1999-12       Impact factor: 4.600

4.  Evaluation of severe insomnia in the general population: results of a European multinational survey.

Authors:  H Chevalier; F Los; D Boichut; M Bianchi; D J Nutt; G Hajak; J Hetta; G Hoffmann; C Crowe
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

5.  Eight weeks of non-nightly use of zolpidem for primary insomnia.

Authors:  J K Walsh; T Roth; A Randazzo; M Erman; A Jamieson; M Scharf; P K Schweitzer; J C Ware
Journal:  Sleep       Date:  2000-12-15       Impact factor: 5.849

6.  Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study.

Authors:  R Cluydts; K Peeters; I de Bouyalsky; J Lavoisy
Journal:  J Int Med Res       Date:  1998 Jan-Feb       Impact factor: 1.671

7.  Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.

Authors:  J Nelson; G Chouinard
Journal:  Can J Clin Pharmacol       Date:  1999

8.  Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases.

Authors:  G Hajak; B Bandelow
Journal:  Int Clin Psychopharmacol       Date:  1998-07       Impact factor: 1.659

9.  Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening--temporal stability of subtypes in a longitudinal study on general practice attenders.

Authors:  F Hohagen; C Käppler; E Schramm; D Riemann; S Weyerer; M Berger
Journal:  Sleep       Date:  1994-09       Impact factor: 5.849

10.  The distribution and clinical significance of sleep time misperceptions among insomniacs.

Authors:  J D Edinger; A I Fins
Journal:  Sleep       Date:  1995-05       Impact factor: 5.849

View more
  2 in total

1.  Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.

Authors:  Andrew D Krystal; Milton Erman; Gary K Zammit; C Soubrane; Thomas Roth
Journal:  Sleep       Date:  2008-01       Impact factor: 5.849

2.  Insomnia.

Authors:  Chien-Ming Yang; Arthur J Spielman; Yu-Shu Huang
Journal:  Curr Treat Options Neurol       Date:  2005-09       Impact factor: 3.972

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.